Seyyed-Reza Sadat-Ebrahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seyyed-Reza Sadat-Ebrahimi has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Akbar Molaei
Cardiovascular research center, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 shared publicationsAzizollah Khomahani
Pediatric Health Research Center, Tabriz Children Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publicationsDavoud Ezzati
Department of Psychology, School of Psychology University of Tabriz Tabriz Iran
3 shared publicationsFatemeh Jamshidi
Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran
3 shared publicationsHossein Namdar
Cardiovascular Research Center Tabriz University of Medical Sciences Tabriz Iran
3 shared publicationsMahnaz Sadeghi-Shabestari
Pediatric Health Research Center, Tabriz Children Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications
Latest Publications
- Open Access
- 20 June 2025
- Published by Maad Rayan Publishing Company in International Journal of Drug Research in Clinics
- Vol. 3 (1) , e11
Hub Genes and Therapeutic Pathways of CTRP9 in Cardiac Ischemia/Reperfusion Injury: A Bioinformatics Perspective
Background: Ischemia/reperfusion injury (IRI) is a significant contributor to cardiac morbidity, while therapeutic options remain limited. According to previous evidence, C1q/TNF-related protein 9 (CTRP9), an adipokine with cardiometabolic regulatory properties, may serve as a potential modulator of myocardial injury. In this study, comprehensive bioinformatics analyses were primarily employed to identify hub genes and elucidate key therapeutic pathways associated with CTRP9 in the context of IRI. Methods: An interrelation analysis of hub genes was conducted to identify direct and indirect interactions. The resulting network and enrichment data were extracted from Cytoscape-GeneMANIA3.6.0, based on a genome-wide human interaction map, for further analysis and visualization. Results: Protein-protein interaction networks and functional enrichment analyses revealed that CTRP9 exerts cardioprotective effects primarily through the activation of adenosine monophosphate-activated protein kinase (AMPK) signaling, which leads to reduced cardiomyocyte apoptosis and enhanced angiogenesis. Notably, bioinformatics data suggested several downstream effectors, such as ucp1, gsk3b, and rps6kb1, as well as collagen-related genes (i.e., col4a2, col14a1, and col18a1), linked to the beneficial effects of CTRP9, considering it a promising therapeutic option related to IRI. Conclusion: These findings recommend several hub genes and pathways that may serve as novel therapeutic targets, highlighting the potential of CTRP9-based interventions for managing IRI-induced cardiac damage and improving clinical outcomes, particularly in cases of myocardial damage caused by IRI. Uncovering all possible underlying mechanisms could enhance our ability to better address the pathological sequelae following IRI.
- 20 June 2025
- Published by Maad Rayan Publishing Company in International Journal of Drug Research in Clinics
- Vol. 3 (1) , e11
Open AccessHub Genes and Therapeutic Pathways of CTRP9 in Cardiac Ischemia/Reperfusion Injury: A Bioinformatics Perspective
Background: Ischemia/reperfusion injury (IRI) is a significant contributor to cardiac morbidity, while therapeutic options remain limited. According to previous evidence, C1q/TNF-related protein 9 (CTRP9), an adipokine with cardiometabolic regulatory properties, may serve as a potential modulator of myocardial injury. In this study, comprehensive bioinformatics analyses were primarily employed to identify hub genes and elucidate key therapeutic pathways associated with CTRP9 in the context of IRI. Methods: An interrelation analysis of hub genes was conducted to identify direct and indirect interactions. The resulting network and enrichment data were extracted from Cytoscape-GeneMANIA3.6.0, based on a genome-wide human interaction map, for further analysis and visualization. Results: Protein-protein interaction networks and functional enrichment analyses revealed that CTRP9 exerts cardioprotective effects primarily through the activation of adenosine monophosphate-activated protein kinase (AMPK) signaling, which leads to reduced cardiomyocyte apoptosis and enhanced angiogenesis. Notably, bioinformatics data suggested several downstream effectors, such as ucp1, gsk3b, and rps6kb1, as well as collagen-related genes (i.e., col4a2, col14a1, and col18a1), linked to the beneficial effects of CTRP9, considering it a promising therapeutic option related to IRI. Conclusion: These findings recommend several hub genes and pathways that may serve as novel therapeutic targets, highlighting the potential of CTRP9-based interventions for managing IRI-induced cardiac damage and improving clinical outcomes, particularly in cases of myocardial damage caused by IRI. Uncovering all possible underlying mechanisms could enhance our ability to better address the pathological sequelae following IRI.
- Open Access
- 25 April 2024
- Published by Wiley in Journal of General and Family Medicine
- Vol. 25 (4) , 198-205
Strict association between development of psychological conditions and hypertension incidence: A cross‐sectional study
Background/Aims: Previous studies indicated a significant association between mental disorders and cardiovascular diseases, including heart failure (HF) and coronary artery disease (CAD) with comorbidity hypertension (HTN), and vice versa, leading to a challenge in the final decision. To resolve this issue, we aimed to exclude comorbidities and further assessed to better find any association between mental disorders and cardiovascular diseases (CVD).Methods: The cross‐sectional study involved 300 participants: 100 with HTN (without HF or CAD), 100 with HF (without HTN or CAD), 100 with CAD (without HTN or HF), and 100 healthy individuals as a control group. To evaluate depression, anxiety, and stress levels, the Depression, Anxiety, and Stress Scale – 21 (DASS‐21) was applied. For further analysis, the SPSS ver.20 was used.Results: The analysis showed that the score of depression, anxiety, and stress was higher in the HTN patients compared to the control (p < 0.001), CAD (p < 0.001), and HF (p < 0.001) groups, respectively. However, no significant differences were observed between the other study groups. Notably, patients with HF and CAD without concurrent HTN had similar psychological distress levels to healthy participants.Conclusion: The present study emphasized the higher prevalence of psychological distress in HTN patients and suggests a requirement for further research regarding the etiology involved in this association.
- 25 April 2024
- Published by Wiley in Journal of General and Family Medicine
- Vol. 25 (4) , 198-205
Open AccessStrict association between development of psychological conditions and hypertension incidence: A cross‐sectional study
Background/Aims: Previous studies indicated a significant association between mental disorders and cardiovascular diseases, including heart failure (HF) and coronary artery disease (CAD) with comorbidity hypertension (HTN), and vice versa, leading to a challenge in the final decision. To resolve this issue, we aimed to exclude comorbidities and further assessed to better find any association between mental disorders and cardiovascular diseases (CVD).Methods: The cross‐sectional study involved 300 participants: 100 with HTN (without HF or CAD), 100 with HF (without HTN or CAD), 100 with CAD (without HTN or HF), and 100 healthy individuals as a control group. To evaluate depression, anxiety, and stress levels, the Depression, Anxiety, and Stress Scale – 21 (DASS‐21) was applied. For further analysis, the SPSS ver.20 was used.Results: The analysis showed that the score of depression, anxiety, and stress was higher in the HTN patients compared to the control (p < 0.001), CAD (p < 0.001), and HF (p < 0.001) groups, respectively. However, no significant differences were observed between the other study groups. Notably, patients with HF and CAD without concurrent HTN had similar psychological distress levels to healthy participants.Conclusion: The present study emphasized the higher prevalence of psychological distress in HTN patients and suggests a requirement for further research regarding the etiology involved in this association.
- Open Access
- 30 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (23) , 3575
Myocardial and Vascular Involvement in Patients with Takayasu Arteritis: A Cardiovascular MRI Study
We aimed to explore the cardiovascular magnetic resonance (CMR) of Takayasu arteritis (TA) and its cardiovascular complications. CMR was conducted on 37 TA patients and 28 healthy individuals. We evaluated the CMR findings and adverse cardiovascular complications at the time of the CMR (ACCCMR). After 8 to 26 months, the major adverse cardiac and cerebrovascular events (MACCEs) were evaluated. The TA included 25 women (67.6%), aged 36 ± 16 years old, and 28 age- and sex-matched healthy controls. Left ventricular (LV) ejection fraction was significantly lower in the TA group than in the control group (51 ± 9% vs. 58 ± 1.7%; p < 0.001). Aortic mural edema was present in 34 patients (92%) and aortic mural hyperenhancement in 36 (97%). Left ventricular global longitudinal strain (LVGLS) was significantly lower in the TA group (median [interquartile range] = 13.70 [3.27] vs. 18.08 [1.35]; p < 0.001). ACCCMR was seen in 13 TA patients (35.1%), with the most common cardiac complication being myocarditis (16.2%). During a median follow-up of 18 months (8–26 months), nine patients developed MACCEs, of which the most common was cerebrovascular accident in five (13.5%). The LVGLS of the CMR had the strongest association with complications. Myocardial strain values, especially LVGLS, can reveal concurrent and future cardiovascular complications in TA patients.
- 30 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (23) , 3575
Open AccessMyocardial and Vascular Involvement in Patients with Takayasu Arteritis: A Cardiovascular MRI Study
We aimed to explore the cardiovascular magnetic resonance (CMR) of Takayasu arteritis (TA) and its cardiovascular complications. CMR was conducted on 37 TA patients and 28 healthy individuals. We evaluated the CMR findings and adverse cardiovascular complications at the time of the CMR (ACCCMR). After 8 to 26 months, the major adverse cardiac and cerebrovascular events (MACCEs) were evaluated. The TA included 25 women (67.6%), aged 36 ± 16 years old, and 28 age- and sex-matched healthy controls. Left ventricular (LV) ejection fraction was significantly lower in the TA group than in the control group (51 ± 9% vs. 58 ± 1.7%; p < 0.001). Aortic mural edema was present in 34 patients (92%) and aortic mural hyperenhancement in 36 (97%). Left ventricular global longitudinal strain (LVGLS) was significantly lower in the TA group (median [interquartile range] = 13.70 [3.27] vs. 18.08 [1.35]; p < 0.001). ACCCMR was seen in 13 TA patients (35.1%), with the most common cardiac complication being myocarditis (16.2%). During a median follow-up of 18 months (8–26 months), nine patients developed MACCEs, of which the most common was cerebrovascular accident in five (13.5%). The LVGLS of the CMR had the strongest association with complications. Myocardial strain values, especially LVGLS, can reveal concurrent and future cardiovascular complications in TA patients.
- Open Access
- 26 November 2020
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 20 (1) , 1-2
Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
An amendment to this paper has been published and can be accessed via the original article.
- 26 November 2020
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 20 (1) , 1-2
Open AccessCorrection to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
An amendment to this paper has been published and can be accessed via the original article.
- Open Access
- 21 October 2020
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 20 (1) , 1-8
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
Background: Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.Methods: This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)—four vials daily for 3 days (in addition to initial treatment), while the other group received a placebo. Patients’ demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.Results: Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively;P = 0.025). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001–0.815];P = 0.042).Conclusions: Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.Trial registration: A study protocol was registered at the Iranian Registry of Clinical Trials (www.IRCT.ir), numberIRCT20200501047259N1. It was registered retrospectively on May 17th, 2020.
- 21 October 2020
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 20 (1) , 1-8
Open AccessThe use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
Background: Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.Methods: This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)—four vials daily for 3 days (in addition to initial treatment), while the other group received a placebo. Patients’ demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.Results: Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively;P = 0.025). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001–0.815];P = 0.042).Conclusions: Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.Trial registration: A study protocol was registered at the Iranian Registry of Clinical Trials (www.IRCT.ir), numberIRCT20200501047259N1. It was registered retrospectively on May 17th, 2020.
- Open Access
- 16 October 2020
- Published by Springer Nature in Research Square
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: A randomised placebo-controlled double-blind clinical trial
Background: Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.Methods: This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)—four vials daily for three days (in addition to initial treatment), while the other group received a placebo. Patients’ demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.Results: Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; P = 0.022). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001–0.815]; P = 0.042).Conclusions: Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.Trial registration: A study protocol was registered at the Iranian Registry of Clinical Trials (www.IRCT.ir), number IRCT20200501047259N1. It was registered retrospectively on May 17th, 2020.
- 16 October 2020
- Published by Springer Nature in Research Square
Open AccessThe use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: A randomised placebo-controlled double-blind clinical trial
Background: Coronavirus disease 2019 (COVID-19) has infected people in many countries worldwide. Discovering an effective treatment for this disease, particularly in severe cases, has become the subject of intense scientific investigation. Therefore, the objective of this study was to evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection.Methods: This study was conducted as a randomized placebo-controlled double-blind clinical trial. Fifty-nine patients with severe COVID-19 infection who did not respond to initial treatments were randomly assigned into two groups. One group received IVIg (human)—four vials daily for three days (in addition to initial treatment), while the other group received a placebo. Patients’ demographic, clinical, and select laboratory test results, as well as the occurrence of in-hospital mortality, were recorded.Results: Among total study subjects, 30 patients received IVIg and 29 patients received a placebo. Demographics, clinical characteristics, and laboratory tests were not statistically different (P > 0.05) between the two groups. The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; P = 0.022). Multivariate regression analysis demonstrated that administration of IVIg did indeed have a significant impact on mortality rate (aOR = 0.003 [95% CI: 0.001–0.815]; P = 0.042).Conclusions: Our study demonstrated that the administration of IVIg in patients with severe COVID-19 infection who did not respond to initial treatment could improve their clinical outcome and significantly reduce mortality rate. Further multicenter studies with larger sample sizes are nonetheless required to confirm the appropriateness of this medication as a standard treatment.Trial registration: A study protocol was registered at the Iranian Registry of Clinical Trials (www.IRCT.ir), number IRCT20200501047259N1. It was registered retrospectively on May 17th, 2020.
- Open Access
- 21 July 2020
- Published by Springer Nature in Research Square
Hypertension But Not Heart Failure or Coronary Artery Disease is Associated with Mental Disorders
Background: Previous studies have emphasized the significant association between depression, anxiety, and stress and hypertension (HTN), heart failure (HF), and coronary artery disease (CAD). However, among included patients with HF or CAD in those studies, there were considerable proportions of patients with concomitant HTN and vice versa leading to some possible bias in final estimations. Therefore, we aimed to exclude those patients with concomitant diseases and reassess the association between these three prevalent cardiovascular diseases with three important psychological disorders. Methods: In this cross-sectional study, 300 patients were evaluated, including 100 with HTN (without a history or concomitant HF or CAD), 100 with HF (without HTN or CAD), and 100 with CAD (without HTN or HF). Moreover, 100 healthy volunteers were considered as the control group. Depression Anxiety Stress Scale 21 was used to measure the magnitude of depression, anxiety, and stress. Result: The average scores of 4.6, 9.1, 3.7, and 4.4 for depression, 3.9, 11.1, 4.1, and 3.6 for anxiety and 6.5, 13.6, 5.2, and 5.4 for stress were detected in control, HTN, CAD, and HF groups, respectively. The depression, anxiety, and stress scores of HTN group were significantly higher than the control (pConclusion: Our study demonstrated a significantly higher magnitude of psychological disorders in patients with HTN. However, their magnitude in patients with HF and CAD without concomitant HTN were similar to those in healthy participants.
- 21 July 2020
- Published by Springer Nature in Research Square
Open AccessHypertension But Not Heart Failure or Coronary Artery Disease is Associated with Mental Disorders
Background: Previous studies have emphasized the significant association between depression, anxiety, and stress and hypertension (HTN), heart failure (HF), and coronary artery disease (CAD). However, among included patients with HF or CAD in those studies, there were considerable proportions of patients with concomitant HTN and vice versa leading to some possible bias in final estimations. Therefore, we aimed to exclude those patients with concomitant diseases and reassess the association between these three prevalent cardiovascular diseases with three important psychological disorders. Methods: In this cross-sectional study, 300 patients were evaluated, including 100 with HTN (without a history or concomitant HF or CAD), 100 with HF (without HTN or CAD), and 100 with CAD (without HTN or HF). Moreover, 100 healthy volunteers were considered as the control group. Depression Anxiety Stress Scale 21 was used to measure the magnitude of depression, anxiety, and stress. Result: The average scores of 4.6, 9.1, 3.7, and 4.4 for depression, 3.9, 11.1, 4.1, and 3.6 for anxiety and 6.5, 13.6, 5.2, and 5.4 for stress were detected in control, HTN, CAD, and HF groups, respectively. The depression, anxiety, and stress scores of HTN group were significantly higher than the control (pConclusion: Our study demonstrated a significantly higher magnitude of psychological disorders in patients with HTN. However, their magnitude in patients with HF and CAD without concomitant HTN were similar to those in healthy participants.
- Open Access
- 17 June 2020
- Published by Springer Nature in Research Square
Hypertension but Not Heart Failure or Coronary Artery Disease is Associated With Mental Disorders
Background Previous studies have emphasized the significant association between depression, anxiety, and stress and hypertension (HTN), heart failure (HF), and coronary artery disease (CAD). However, among included patients with HF or CAD in those studies, there were considerable proportions of patients with concomitant HTN and vice versa leading to some possible bias in final estimations. Therefore, we aimed to exclude those patients with concomitant diseases and reassess the association between these three prevalent cardiovascular diseases with three important psychological disorders. Methods In this cross-sectional study, 300 patients were evaluated, including 100 with HTN (without a history or concomitant HF or CAD), 100 with HF (without HTN or CAD), and 100 with CAD (without HTN or HF). Moreover, 100 healthy volunteers were considered as the control group. Depression Anxiety Stress Scale 21 was used to measure the magnitude of depression, anxiety, and stress. Result The average scores of 4.6, 9.1, 3.7, and 4.4 for depression, 3.9, 11.1, 4.1, and 3.6 for anxiety and 6.5, 13.6, 5.2, and 5.4 for stress were detected in control, HTN, CAD, and HF groups, respectively. The depression, anxiety, and stress scores of HTN group were significantly higher than the control (p < 0.05), CAD (p < 0.05) and HF (p < 0.05) groups; this is while these scores were not significantly different between other study groups (p > 0.05). Conclusion Our study demonstrated a significantly higher magnitude of psychological disorders in patients with HTN. However, their magnitude in patients with HF and CAD without concomitant HTN were similar to those in healthy participants.
- 17 June 2020
- Published by Springer Nature in Research Square
Open AccessHypertension but Not Heart Failure or Coronary Artery Disease is Associated With Mental Disorders
Background Previous studies have emphasized the significant association between depression, anxiety, and stress and hypertension (HTN), heart failure (HF), and coronary artery disease (CAD). However, among included patients with HF or CAD in those studies, there were considerable proportions of patients with concomitant HTN and vice versa leading to some possible bias in final estimations. Therefore, we aimed to exclude those patients with concomitant diseases and reassess the association between these three prevalent cardiovascular diseases with three important psychological disorders. Methods In this cross-sectional study, 300 patients were evaluated, including 100 with HTN (without a history or concomitant HF or CAD), 100 with HF (without HTN or CAD), and 100 with CAD (without HTN or HF). Moreover, 100 healthy volunteers were considered as the control group. Depression Anxiety Stress Scale 21 was used to measure the magnitude of depression, anxiety, and stress. Result The average scores of 4.6, 9.1, 3.7, and 4.4 for depression, 3.9, 11.1, 4.1, and 3.6 for anxiety and 6.5, 13.6, 5.2, and 5.4 for stress were detected in control, HTN, CAD, and HF groups, respectively. The depression, anxiety, and stress scores of HTN group were significantly higher than the control (p < 0.05), CAD (p < 0.05) and HF (p < 0.05) groups; this is while these scores were not significantly different between other study groups (p > 0.05). Conclusion Our study demonstrated a significantly higher magnitude of psychological disorders in patients with HTN. However, their magnitude in patients with HF and CAD without concomitant HTN were similar to those in healthy participants.
- Open Access
- 17 June 2020
- Published by Springer Nature in BMC Pediatrics
- Vol. 20 (1) , 1-5
A case of pheochromocytoma presenting with cardiac manifestation: case report
Background: Pheochromocytomas are rare tumors originating in chromaffin cells which predominantly are located in adrenal glands. Sustained or paroxysmal hypertension (HT) is the most frequent sign of pheochromocytoma. In some cases, it is associated with the classic triad including episodic headaches, sudoresis, and tachycardia; however, we present a case of pheochromocytoma with first presentation of cardiomyopathy. Case presentation: The authors describe a rare case of a pheochromocytoma which was first presented with cardiomyopathy in a 7-year-old patient. The patient was admitted with malaise, abdominal pain, polydipsia, and myalgia. Further evaluations revealed hyperglycemia, mild dehydration and sinus tachycardia but no HT. Echocardiography demonstrated some of the signs of cardiomyopathy which was incorrectly diagnosed as viral myocarditis. The patient was discharged with this diagnosis but he presented again with HT crisis a few months later. A diagnosis of pheochromocytoma was assigned after the evaluation of the HT secondary causes. The diagnosis was confirmed by metanephrine assay and the tumor was localized in the adrenal gland using the abdominal MRI. Conclusion: Pheochromocytoma can present itself with normotensive cardiomyopathy. Therefore, the possibility of pheochromocytoma should be considered in patients with cardiomyopathy especially in those with positive familial history.
- 17 June 2020
- Published by Springer Nature in BMC Pediatrics
- Vol. 20 (1) , 1-5
Open AccessA case of pheochromocytoma presenting with cardiac manifestation: case report
Background: Pheochromocytomas are rare tumors originating in chromaffin cells which predominantly are located in adrenal glands. Sustained or paroxysmal hypertension (HT) is the most frequent sign of pheochromocytoma. In some cases, it is associated with the classic triad including episodic headaches, sudoresis, and tachycardia; however, we present a case of pheochromocytoma with first presentation of cardiomyopathy. Case presentation: The authors describe a rare case of a pheochromocytoma which was first presented with cardiomyopathy in a 7-year-old patient. The patient was admitted with malaise, abdominal pain, polydipsia, and myalgia. Further evaluations revealed hyperglycemia, mild dehydration and sinus tachycardia but no HT. Echocardiography demonstrated some of the signs of cardiomyopathy which was incorrectly diagnosed as viral myocarditis. The patient was discharged with this diagnosis but he presented again with HT crisis a few months later. A diagnosis of pheochromocytoma was assigned after the evaluation of the HT secondary causes. The diagnosis was confirmed by metanephrine assay and the tumor was localized in the adrenal gland using the abdominal MRI. Conclusion: Pheochromocytoma can present itself with normotensive cardiomyopathy. Therefore, the possibility of pheochromocytoma should be considered in patients with cardiomyopathy especially in those with positive familial history.
- 1 February 2020
- Vol. 8 (2) , 10911-10928
Diagnostic and Prognostic Value of Cardiac Biomarkers in Children with Kawasaki Disease: A State-of-the-Art Review
- 1 February 2020
- Vol. 8 (2) , 10911-10928
Diagnostic and Prognostic Value of Cardiac Biomarkers in Children with Kawasaki Disease: A State-of-the-Art Review